A comparative study of gemcitabine/doxorubicin and cyclophosphamide/doxorubicin combinations in first-line metastatic breast cancer
| Autor: | L. Djellali, H. Khellafi, M. Yamouni, Y. Beldjilali, K. A. Benhadji, A. Abdelaoui |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Oncology
Drug Cancer Research medicine.medical_specialty Cyclophosphamide business.industry media_common.quotation_subject Pharmacology medicine.disease Metastatic breast cancer Gemcitabine Breast cancer Internal medicine Toxicity medicine Clinical endpoint Doxorubicin business medicine.drug media_common |
| Zdroj: | Journal of Clinical Oncology. 26:1050-1050 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2008.26.15_suppl.1050 |
| Popis: | 1050 Background: Doxorubicin is a major drug for the treatment of breast cancer. D combination with cyclophosphamide (C) is commonly used in the treatment of breast cancer. Previous studies reported promising activity of the combination of gemcitabine (G) and D. This study was conducted to assess the efficacy and safety of GD and CD combination regimens in previously untreated patients with metastatic breast cancer (MBC). Methods: Previously untreated patients (pts) with MBC received either GD (G 1,200 mg/m2 and D 25 mg/m2 both on days 1 and 8) or CD (C 600 mg/m2 and D 60 mg/m2 on day 1). Cycles were repeated every 21 days. Treatments were continued until disease progression or unacceptable toxicity. Primary endpoint was overall response rate (ORR). Secondary endpoints were time to progression (TTP), overall survival (OS) and toxicity assessment. Results: 109 pts were enrolled in this trial, 55 in GD arm and 54 in CD arm. Median age was 41 years (GD) and 45 years (CD). Most patients were anthracyclines na... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|